Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles British Journal of Haematology Year : 2021

Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy

Abstract

No abstract available

Domains

Cancer
Embargoed file
Embargoed file
Visibility date is undetermined

Dates and versions

inserm-03388040 , version 1 (20-10-2021)

Identifiers

Cite

Thomas Gastinne, Amandine Le Bourgeois, Marianne Coste‐burel, Thierry Guillaume, Pierre Peterlin, et al.. Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy. British Journal of Haematology, 2021, Online ahead of print. ⟨10.1111/bjh.17818⟩. ⟨inserm-03388040⟩
24 View
27 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More